NEW YORK / Apr 21, 2025 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31st, 2025 after the markets close on Thursday, May 8th, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day.
Conference call and webcast details:
Thursday, May 8th, 2025
5:00 p.m. ET
1-800-717-1738 (U.S.)
1-646-307-1865 (international)
Conference ID: 65854
To access the Call me™ feature, which avoids the need to wait for an operator, click https://emportal.ink/4lbapGU.
A webcast of the conference call can be accessed under Events on the Investors section of the Company’s website at https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and medical transport solutions. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
Last Trade: | US$2.05 |
Daily Change: | -0.08 -3.54 |
Daily Volume: | 352,893 |
Market Cap: | US$207.630M |
February 27, 2025 February 19, 2025 February 10, 2025 December 18, 2024 December 10, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load